Molecular pharmacology of topiramate: Managing seizures and preventing migraine

Headache

Volumn 45, Issue SUPPL. 1, 2005, Pages

  White, H Steve ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Epilepsy; Migraine; Prevention; Topiramate; Voltage gated channels

Indexed keywords

4 AMINOBUTYRIC ACID; CARBONATE DEHYDRATASE; N METHYL DEXTRO ASPARTIC ACID; TOPIRAMATE; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

CONFORMATION; DRUG EFFICACY; FOCAL EPILEPSY; HUMAN; MIGRAINE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE;

ANIMALS; ANTICONVULSANTS; FRUCTOSE; HUMANS; ION CHANNELS; MIGRAINE DISORDERS; SEIZURES;

EID: 17244372257     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.4501006.x     Document Type: Review

References (50)

1. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia. 1994;35(suppl 2):450-460.
2. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(suppl 1):S17-S20.
3. Kimishima K, Want Y, Tanabe T, et al. Anticonvulsant activities and properties of topiramate. Jpn J Pharmacol. 1992;58(suppl 1):S11P.
4. Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. 1996;24:73-77.
5. Nakamura F, Hiyoshi T, Kudo T, Yagi K, Seino M. Anticonvulsant effect of topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfate] on amygdaloid kindled seizures in the cat. Jpn J Psychiatry Neurol. 1993;47:394-395.
6. Reissmuller E, Ebert U, Loscher W. Anticonvulsant efficacy of topiramate in phenytoin-resistant kindled rats. Epilepsia. 2000;41:372-379.
7. Loscher W, Reissmuller E, Ebert U. Kindling alters the anticonvulsant efficacy of phenytoin in Wistar rats. Epilepsy Res. 2000;39:211-220.
8. Dalby NO, Mody I. The process of epileptogenesis: a pathophysiological approach. Curr Opin Neurol. 2001;14:187-192.
9. Dichter MA. Emerging insights into mechanisms of epilepsy: implications for new antiepileptic drug development. Epilepsia. 1994;35(suppl 4):S51-S57.
10. Heinemann U, Draguhn A, Picker E, Stabel J, Zhang C.L. Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia. 1994;35(suppl 5):S10-S21.
11. Macdonald RL, Meldrum BS. General principles. Principles of antiepileptic drug action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York, NY: Raven Press, Ltd.; 1995:61-77.
12. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36(suppl 2):S2-S12.
13. Kors E, Haan J, Ferrari M. Migraine genetics. Curr Pain Headache Rep. 2003;7:212-217.
14. Ferrari MD. Migraine. Lancet. 1998;351:1043-1051.
15. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA. 2001;98:4687-4692.
16. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996;384:560-564.
17. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002;346:257-270.
18. Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003;61(8 suppl 4):S9-S20.
19. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3-S9.
20. White HS. Topiramate: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:719-726.
21. 2+ currents in CA1 pyramidal neurons in vitro. Epilepsia. 1998;39(suppl 6):44.
22. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(suppl 1):S35-S39.
23. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42:210-220.
24. Kanda T, Kurokawa M, Tamura S, et al. Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci. 1996;59:1607-1616.
25. Alves OL, Doyle AJ, Clausen T, Gilman C, Bullock R. Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. Ann N Y Acad Sci. 2003;993:25-34; discussion, 48-53.
26. McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia. 2000;41(suppl 1):S21-S24.
27. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett. 1997;231:123-126.
28. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia. 1993;34(suppl 2):123.
29. Severt L, Coulter DA, Sombati S, DeLorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia. 1995;36(suppl 4):S38.
30. Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003;23:7069-7074.
31. Angehagen M, Ben-Menachem E, Ronnback L, Hansson E. Topiramate protects against glutamate-and kainate-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res. 2003;54:63-71.
32. Poulsen CF, Simeone TA, Maar TE, Smith-Swintosky V, White HS, Schousboe A. Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochem Res. 2004;29:275-282.
33. Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 2000;41(suppl 1):S45-S47.
34. Qian J, Noebels JL. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res. 2003;55:225-233.
35. Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004;46:1097-1104.
36. Brown SD, Wolf HH, Swinyard EA, Twyman RE, White HS. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia. 1993;34(suppl 2):122-123.
37. White HS, Brown D, Skeen GA, Wolf HH, Twyman RE. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia. 1995;36(suppl 3):S39-S40.
38. Simeone TA, McClellan AML, Twyman RE, White HS. Direct activation of the recombinant a2b2g2S GABAA receptor by the novel anticonvulsant topiramate [abstract]. Soc Neurosci. 2002;26:631.
39. Gordey M, DeLorey TM, Olsen RW. Differential sensitivity of recombinant GABA(A) receptors expressed in Xenopus oocytes to modulation by topiramate. Epilepsia. 2000;41(suppl 1):S25-S29.
40. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28:167-179.
41. White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia. 1992;33:564-572.
42. Petroff OA, Hyder F, Mattson RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology. 1999;52:473-478.
43. Sills GJ, Leach JP, Kilpatrick WS, Fraser CM, Thompson GG, Brodie MJ. Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt. Epilepsia. 2000;41(suppl 1):S30-S34.
44. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(suppl 1):S52-S60.
45. Russo E, Constanti A, Ferreri G, Citraro R, De Sarro G. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology. 2004;46:865-878.
46. 2 on excitatory transmission apparently caused by changes in intracellular pH in the rat hippocampal slice. Brain Res. 1996;706:210-216.
47. A receptors. Science. 1995;269:977-981.
48. Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000;62:509-525.
49. De Vries P, Villalon CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol. 1999;375:61-74.
50. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. Neurology. 2003;60(suppl 1):A238-A239.